Drug Type Small molecule drug |
Synonyms AUR-109, ODM 203 |
Target |
Action antagonists, inhibitors |
Mechanism DDR1 antagonists(Discoidin domain receptor 1 antagonists), SIK2 inhibitors(Serine/threonine-protein kinase SIK2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H21F2N5O2S |
InChIKeyZJFCBQXPTQSTCZ-UHFFFAOYSA-N |
CAS Registry1430723-35-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of large intestine | Phase 2 | India | 09 Nov 2024 | |
HER2 Positive Colorectal Cancer | Phase 2 | India | 09 Nov 2024 | |
Ovarian Epithelial Carcinoma | Phase 2 | India | 09 Nov 2024 | |
Renal Cell Carcinoma | Phase 2 | India | 09 Nov 2024 | |
Solid tumor | Phase 2 | Finland | 21 Apr 2016 | |
Bladder Cancer | Phase 2 | India | - | |
Breast Cancer | Phase 2 | India | - | |
Fibrosis, Liver | Phase 2 | India | - | |
Liver Cancer | Phase 2 | India | - | |
Lung Cancer | Phase 2 | India | - |
Phase 1/2 | 84 | qgkfzyvyym(hjsqpwshnr) = kwdkwyzkeh atkurnqgqy (npbsiittkr ) View more | Positive | 01 Dec 2020 | |||
Phase 1/2 | 84 | nyjnbzfafy(cpjcflspuu) = 41% nvyskjnrsv (zonnroqnux ) View more | Positive | 22 Oct 2018 |